Drugs / BMTP-11
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00872157 | Mar 2009 → Oct 2015 | prostate cancer | M.D. Anderson Cancer Center | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BMTP-11 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00872157 ↗ |
| Known as | bone metastasis-targeting peptidomimetic-11 | “The authors generated a ligand-directed, peptidomimetic drug (bone metastasis-targeting peptidomimetic-11 [BMTP-11]) for IL-11Rα-based human tumor vascular targeting.” PMID 25832466 ↗ Apr 2015 |
| Route | Intravenous | “you will receive BMTP-11 though a needle into your vein over 2 hours” NCT00872157 ↗ |